Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical TechnologyKOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.Clinical DataMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalryNext: AZ claims another win for Imfinzi in frontline liver cancer Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
